Adanma Ayanambakkam, MD, MS, discusses the safety profile of darlifarnib plus cabozantinib in ccRCC.
Adanma Ayanambakkam, MD, MS
Advertisement
Adanma Ayanambakkam, MD, MS, is the associate program director of the Hematology Oncology Fellowship & Director of Infusion Services at Stephenson Cancer Center at the University of Oklahoma Health Sciences Center.
Articles by Adanma Ayanambakkam, MD, MS
Adanma Ayanambakkam, MD, MS, discusses efficacy data from the phase 1a/1b FIT-001 trial.
Adanma Ayanambakkam, MD, MS, discusses the mechanism of action of darlifarnib in ccRCC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
2
ASCO 2026 Ushers In a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum
3
FDA Flashback: Breast Cancer Decisions and News From May 2026
4
Dr Mathews on Updated Data From the RAINFOL-01 Trial in Advanced Ovarian Cancer
5